Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Significant Increase in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 56,600 shares, an increase of 625.6% from the October 31st total of 7,800 shares. Based on an average daily volume of 326,400 shares, the days-to-cover ratio is presently 0.2 days.

Appili Therapeutics Stock Performance

Appili Therapeutics stock traded down $0.00 during mid-day trading on Friday, reaching $0.03. The stock had a trading volume of 50,000 shares, compared to its average volume of 101,719. Appili Therapeutics has a one year low of $0.01 and a one year high of $0.05. The company has a 50-day moving average price of $0.02 and a two-hundred day moving average price of $0.03.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.